

**AbbVie Clinical Pharmacology Research Unit**  
Information Sheet  
www.abbviephase1.com

**Sunflower**

**Check In: Wednesday, 25 May 2022**

**Study drug and design:**

AbbVie is testing an investigational drug, which is not approved by the Food and Drug Administration (FDA) or any health authority and is not currently available on the market. The objective of this study is to determine safety, tolerability and pharmacokinetics (the amount of drug absorbed into your blood stream and how your body handles the drug) of the investigational drug in healthy subjects.

**Minimum Subject Selection Criteria:**

*YOU may be eligible to take part in this clinical study if you meet the following conditions:*

- ◆ Healthy men and women between 18 to 55 years of age.
- ◆ Average weight for height ( $\geq$ BMI 18 to  $\leq$ 29.9 kg/m<sup>2</sup>)
- ◆ Females must be non-childbearing: permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy), or postmenopausal.
- ◆ No history of any significant cardiac, respiratory, (except mild asthma as a child) renal, hepatic, gastrointestinal, hematologic, or psychiatric disease or disorder, or any uncontrolled medical illness.
- ◆ No history of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to study drug administration.
- ◆ Not taking any medications or herbal remedies or supplements.
- ◆ No history of any drug sensitivity or allergy.
- ◆ No vaccination after 25 Apr 2022 or 30 days prior to first dose of study drug, with the exception of the Covid-19 vaccine.
- ◆ No history of drug or alcohol abuse for 6 months.
- ◆ Non-user of tobacco for at least 6 months.
- ◆ NO investigational products after 13 Apr 2022, or 6 weeks (42 days), or 5 half lives of the drug, whichever is longer, prior to first dose of the study drug, or is currently enrolled in another clinical study or was previously enrolled in this study.
- ◆ No drugs by injection after 25 Apr 2022, or 30 days.
- ◆ No blood or blood product donation after 30 Mar 2022, or 8 weeks.

**Screenings at ACPRU in Grayslake**

**Screening dates:** *(To find out if you are suitable to take part in this clinical study)*

- ◆ May 03, 04, 05, 06, 09, 10, 11, 12, 13, 16, 17, 18, 19, 20, 2022. **Additional screening dates may be available.**
- ◆ Screening appointments are between the hours of 08:00 and 11:00 and take approximately 3 hours.

**Stipend:**

## AbbVie Clinical Pharmacology Research Unit

### Information Sheet

[www.abbviephase1.com](http://www.abbviephase1.com)

- ◆ **Screening:** \$75.00. (No compensation if urine drug/alcohol/cotinine screen is positive or if BMI is out of range.)
- ◆ **Study:** Compensation of up to \$6,925.00 may be provided if selected and you complete the study.

**Study dates:** *(Please note that these dates and times are subject to change)*

**Must complete all periods and/or follow up visit(s).**

**CHECK IN:** Wednesday, 25 May 2022 at scheduled appointment time.

**CHECK OUT:** Saturday, 11 Jun 2022 at approximately noon.

**FOLLOW UP PHONE CALL:** Wednesday, 22 Jun 2022 at scheduled appointment time.

**(A follow up visit may be required for safety. If this occurs, you will be notified and compensated for your visit time and travel)**

*(Please note that these dates and times are subject to change)*

**Please call our recruiting office at 1-800-827-2778 to schedule an appointment.**